ABIOMED, Inc. is a developer, manufacturer and marketer of medical products that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ABMD’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that ABIOMED could be a solid choice for investors.
Current Quarter Estimates for ABMD
In the past 30 days, four estimates have gone higher for ABIOMED while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 34 cents a share 30 days ago, to 37 cents today, a move of 8.8%.
Current Year Estimates for ABMD
Meanwhile, ABIOMED’s current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.78 per share 30 days ago to $2.21 per share today, an increase of 24.2%.
Bottom Line
The stock has also started to move higher lately, adding 9.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.Learn more >>
Image: Bigstock
Why ABIOMED (ABMD) Could Be Positioned for a Surge
ABIOMED, Inc. is a developer, manufacturer and marketer of medical products that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ABMD’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that ABIOMED could be a solid choice for investors.
Current Quarter Estimates for ABMD
In the past 30 days, four estimates have gone higher for ABIOMED while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 34 cents a share 30 days ago, to 37 cents today, a move of 8.8%.
Current Year Estimates for ABMD
Meanwhile, ABIOMED’s current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.78 per share 30 days ago to $2.21 per share today, an increase of 24.2%.
ABIOMED, Inc. Price and Consensus
ABIOMED, Inc. Price and Consensus | ABIOMED, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 9.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.Learn more >>